Literature DB >> 15990862

Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma.

F M Ross1, A H Ibrahim, A Vilain-Holmes, M O Winfield, L Chiecchio, R K M Protheroe, P Strike, J L Gunasekera, A Jones, C J Harrison, G J Morgan, N C P Cross.   

Abstract

A simple high throughput micro-fluorescence in situ hybridisation technique (FISH) was used to detect chromosome 13 deletions (delta13), immunoglobulin heavy chain (IgH) rearrangements, t(11;14)(q13;q32), t(4;14)(p16;q32), t(14;16)(q23;q32), p53 loss, and numerical changes of chromosomes 3, 6, 7, 9, 10, 11 and 17 in 228 cases of multiple myeloma (MM), including 33 asymptomatic/smouldering MM (SMM). The patients were not part of a clinical trial and were from 30 different hospitals. In all, 98.4% of cases were abnormal, with 43% having IgH rearrangements and 42% Delta13. The low incidence of IgH rearrangements was due to a decrease in this finding with age (P = 0.001) and the relatively high proportion of elderly patients in our study population (41% >70 years old). The incidence of specific IgH translocations was t(4;14) 11%, t(11;14) 16% and t(14;16) 3%. Univariate statistical testing showed delta13 (P = 0.002), and t(14;16) (P = 0.005) to be associated with shorter survival. This effect was exaggerated for patient's aged 70 years or under but no effect on survival was seen for those over 70 years. In younger patients t(4;14) (P = 0.044) and p53 deletion (P < 0.001) were also significant poor prognostic indicators. Multivariate analysis showed delta13 and t(14;16) to be independent prognostic variables when considered with age and clinical parameters.

Entities:  

Mesh:

Year:  2005        PMID: 15990862     DOI: 10.1038/sj.leu.2403857

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  30 in total

1.  The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance.

Authors:  Fiona M Ross; Laura Chiecchio; GianPaolo Dagrada; Rebecca K M Protheroe; David M Stockley; Christine J Harrison; Nicholas C P Cross; Alex J Szubert; Mark T Drayson; Gareth J Morgan
Journal:  Haematologica       Date:  2010-04-21       Impact factor: 9.941

2.  Challenges and Promises of Genetic Stratification of Risk in Multiple Myeloma.

Authors:  Hara Prasad Pati; Prashant Sharma
Journal:  Indian J Hematol Blood Transfus       Date:  2017-01-16       Impact factor: 0.900

3.  Pretreatment 18F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma.

Authors:  Yoshiaki Abe; Kentaro Narita; Hiroki Kobayashi; Akihiro Kitadate; Daisuke Miura; Masami Takeuchi; Eri O'uchi; Toshihiro O'uchi; Kosei Matsue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-28       Impact factor: 9.236

4.  Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma.

Authors:  Jing-jing Huang; Juan Yu; Jiang-yan Li; Yao-ting Liu; Ren-qian Zhong
Journal:  Med Oncol       Date:  2012-03-24       Impact factor: 3.064

5.  Age at diagnosis and loss of heterozygosity on chromosome 1p and 19q in oligodendroglial tumors.

Authors:  M Hergersberg; L Mariani; E Vassella; C Murtin; J Weis; M Moschopulos; H Laeng; H Landolt; A Huber; U Roelcke
Journal:  J Neurooncol       Date:  2006-05-10       Impact factor: 4.130

6.  Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence.

Authors:  James R Cook; Marybeth Hartke; James Pettay; Raymond R Tubbs
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

7.  Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.

Authors:  Laura Chiecchio; Gian Paolo Dagrada; Ashraf H Ibrahim; Elizabet Dachs Cabanas; Rebecca K M Protheroe; David M Stockley; Kim H Orchard; Nicholas C P Cross; Christine J Harrison; Fiona M Ross
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

Review 8.  Genomic complexity of multiple myeloma and its clinical implications.

Authors:  Salomon Manier; Karma Z Salem; Jihye Park; Dan A Landau; Gad Getz; Irene M Ghobrial
Journal:  Nat Rev Clin Oncol       Date:  2016-08-17       Impact factor: 66.675

9.  Complex IGH rearrangements in multiple myeloma: Frequent detection discrepancies among three different probe sets.

Authors:  Gina Y Kim; Ana Gabrea; Yulia N Demchenko; Leif Bergsagel; Anna V Roschke; W Michael Kuehl
Journal:  Genes Chromosomes Cancer       Date:  2014-03-03       Impact factor: 5.006

10.  Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case.

Authors:  Laura Chiecchio; Gian Paolo Dagrada; Rebecca K M Protheroe; David M Stockley; Alastair G Smith; Kim H Orchard; Nicholas C P Cross; Christine J Harrison; Fiona M Ross
Journal:  Haematologica       Date:  2009-05-19       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.